Ballard, C., Corbett, A., Chitramohan, R. and Aarsland, D. (2009). Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. Current Opinion in Psychiatry, 22, 532–540. doi:10.1097/YCO.0b013e32833111f9.
Cohen-Mansfield, J. (1989). Agitation in the elderly. Advances in Psychosomatic Medicine, 19, 101–113.
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A. and Gornbein, J. (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308–2314.
Cummings, J. L., Schneider, E., Tariot, P. N., Graham, S. M. and Memantine MEM-MD-02 Study Group (2006). Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology, 67, 57–63.
Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.
Fox, C.et al. (2012). Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS ONE, 7, e35185. doi:10.1371/journal.pone.0035185.
Galasko, D.et al. (1997). An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11 (Suppl. 2), S33–S39.
Gauthier, S.et al. (2002). Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics, 14, 389–404.
Gauthier, S., Loft, H. and Cummings, J. (2008). Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. International Journal of Geriatric Psychiatry, 23, 537–545.
Gauthier, S.et al. (2010). Management of behavioral problems in Alzheimer's disease. International Psychogeriatrics, 22, 346–372. doi:10.1017/S1041610209991505.
Hachinski, V. C.et al. (1975). Cerebral blood flow in dementia. Archives of Neurology, 32, 632–637.
Herrmann, N. and Gauthier, S. (2008). Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ, 179, 1279–1287. doi:10.1503/cmaj.070804.
Herrmann, N. and Lanctôt, K. L. (2007). Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease. Canadian Journal of Psychiatry, 52, 630–646.
Hort, J.et al. (2010). EFNS guidelines for the diagnosis and management of Alzheimer's disease. European Journal of Neurology, 17, 1236–1248. doi:10.1111/j.1468-1331.2010.03040.x.
Howard, R. J.et al. (2007). Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine, 357, 1382–1392.
Howard, R.et al. (2012). Donepezil and memantine for moderate-to-severe Alzheimer's disease. New England Journal of Medicine, 366, 893–903. doi:10.1056/NEJMoa1106668.
Ihl, R.et al. (2011). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. World Journal of Biological Psychiatry, 12, 2–32. doi:10.3109/15622975.2010.538083.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939–944.
Panisset, M., Roudier, M., Saxton, J. and Boller, F. (1994). Severe impairment battery. A neuropsychological test for severely demented patients. Archives of Neurology, 51, 41–45.
Rabins, P. V., Mace, N. L. and Lucas, M. J. (1982). The impact of dementia on the family. JAMA, 248, 333–335.
Schneider, L. S.et al. (1997). Validity and reliability of the Alzheimer's Disease Cooperative Study – clinical global impression of change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11 (Suppl. 2), S22–S32.
Seitz, D. P., Adunuri, N., Gill, S. S., Gruneir, A., Herrmann, N. and Rochon, P. (2011). Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews, (2), CD008191. doi:10.1002/14651858.CD008191.pub2.
Tariot, P. N.et al. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 291, 317–324.
Wilcock, G. K., Ballard, C. G., Cooper, J. A. and Loft, H. (2008). Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. Journal of Clinical Psychiatry, 69, 341–348.